- Home
- EMPD vs CGTX Comparison
EMPD vs CGTX Comparison
Compare EMPD & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EMPD | CGTX |
|---|---|---|
| Founded | 2020 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.0M | 158.8M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | EMPD | CGTX |
|---|---|---|
| Price | $4.66 | $1.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.88 |
| AVG Volume (30 Days) | ★ 1.0M | 933.6K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,624,202.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.40 | $0.22 |
| 52 Week High | $80.80 | $3.83 |
Technical Indicators
Market Signals| Indicator | EMPD | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 36.83 | 53.10 |
| Support Level | $4.62 | $1.69 |
| Resistance Level | $5.13 | $1.77 |
| Average True Range (ATR) | 0.30 | 0.12 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 5.15 | 75.58 |
Price Performance
Historical ComparisonAbout EMPD Empery Digital Inc.
Empery Digital Inc is an all-electric, off-road powersports vehicle company developing and building electric two and four-wheel motorcycles and utility terrain vehicles, also known as side-by-sides, along with a complete line of upgrades and accessories. The company's products include motorcycle and UTV products that are all-electric and designed for off-road use.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.